CSPC PHARMA (01093): SYH2066 tablets approved for clinical trials in China

CSPC PHARMA (01093) announced that the SYH2066 tablets developed by the group have been approved by the National Medical Products Administration of the People's Republic of China in September 2025 for clinical trials in China. This product is a chemically classified new drug independently developed by the group, which is a new oral small molecule candidate drug targeting respiratory syncytial virus (RSV). The approved indication for this product is for the treatment of respiratory infections caused by RSV. Preclinical studies have shown that the product has good oral bioavailability and pharmacokinetic properties, and can significantly reduce RSV viral titers in disease animal models with high safety. Currently, there are no small molecule drugs targeting RSV on the market domestically or internationally. This product is expected to become an effective treatment for this disease, with high clinical development value.